AGILE THERAPEUTICS INC

Entry into a Material Definitive Agreement On June 26, 2024, the Company filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “SE

Termination of a Material Definitive Agreement As of the Effective Time, the Agile Therapeutics, Inc. 2023 Equity Incentive Plan and all other historical equity

of this Current Report on Form 8-K is incorporated herein by reference into this Item 5.02. Prior to the Effective Time, each of Al Altomari, Sharon Barbari, Sa

. Upon the consummation of the Merger and the final approval by the Financial Industry Regulatory Authority, Inc., the shares of the Company Common Stock will n

. As a result of the Merger, each share of Company Common Stock that was issued and outstanding immediately prior to the Effective Time (except as described in

. As a result of the Merger, at the Effective Time, a change in control of the Company occurred and the Company ceased to exist as a separate corporate entity a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The informati

. In connection with the consummation of the Merger, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in t

Submission of Matters to a Vote of Security Holders. On August 22, 2024, the Company held a special meeting of its stockholders (the “Special Meeting”) to consi

and in Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the l

Financial Statements and Exhibits. (d) Exhibits 2.1* Agreement and Plan of Merger, dated June 25, 2024, by and among Insud Pharma, S.L., Exeltis Project, Inc. a